In Vivo Imaging Facility

体内成像设备

• 批准号: 10254105
• 负责人: Jessie Nedrow
• 金额: $ 22.39万
• 依托单位: UNIVERSITY OF PITTSBURGH AT PITTSBURGH
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-10 至 2025-07-31
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/10254105
• 关键词: Address; Aftercare; Algorithms; Animal Cancer Model; Antigen Receptors; Antineoplastic Agents; Apoptosis; Back; Biological Markers; Budgets; Cancer Center; Cancer Center Support Grant; Cancer Model; Cell Communication; Cell physiology; Cells; Clinical; Clinical Research; Clinical Trials; Clinical assessments; Communication; Contrast Media; Detection; Development; Diagnosis; Disease; Drug Monitoring; Early treatment; Evaluation; Event; FDA approved; Funding; Genomics; Goals; Head and Neck Squamous Cell Carcinoma; Human; Image; Imaging Techniques; Imaging technology; Immune; Immune response; Immunity; Immunotherapy; Journals; Magnetic Resonance Imaging; Malignant Neoplasms; Measurement; Measures; Medical Imaging; Methodology; Methods; Modality; Monitor; Names; Nature; Neoplasm Metastasis; Nuclear; Optics; Peer Review; Pharmacotherapy; Positron-Emission Tomography; Production; Prognosis; Protocols documentation; Publications; Radiogenomics; Radiology Specialty; Radionuclide therapy; Research Personnel; Resource Sharing; Rodent Model; Scanning; Services; Solid Neoplasm; Staging; Testing; Tracer; Treatment Efficacy; Tumor Markers; Tumor Volume; Tumor-infiltrating immune cells; Validation; bench to bedside; bioluminescence imaging; cancer cell; cancer imaging; cancer research center director; cancer therapy; clinical imaging; co-clinical trial; early detection biomarkers; fluorodeoxyglucose; fluorodeoxyglucose positron emission tomography; glucose metabolism; high dimensionality; human model; imaging biomarker; imaging facilities; in vivo; in vivo imaging; in vivo imaging system; melanoma; member; molecular imaging; molecular marker; multimodality; non-invasive imaging; novel; novel therapeutics; pre-clinical; pre-clinical assessment; preclinical imaging; programs; quantitative imaging; radiomics; radiotracer; receptor; recruit; repository; response; targeted agent; theranostics; treatment response; tumor; tumor growth; tumor microenvironment; tumorigenesis

Abstract: In Vivo Imaging Facility (IVIF) Advances in cancer management require the development of new therapies, and state-of-the-art imaging technologies are needed to assess response to those therapies. The Hillman Cancer Center (HCC) In Vivo Imaging Facility (IVIF) provides novel quantitative imaging techniques that trace biomarkers of molecular events and immunotherapy response associated with effective cancer therapy. Validation of advanced imaging techniques that are specific for relevant cellular processes are required to detect and measure the efficacy of novel anticancer therapies and measure early tumoricidal response. As part of this facility, PET tracers targeting various tumor markers and immune cells in the tumor microenvironment, as well as complementary optical and MR methodologies, are being developed to sensitively and specifically quantify drug-cancer cell interactions. The IVIF provides a critical shared resource for testing PET tracers in in vivo rodent models of cancer and validating promising agents in humans through quantitative imaging trials. The overall goal of the IVIF is to provide pre-clinical and clinical imaging services to HCC investigators to assist in visualizing mechanisms of biomarker action, provide approaches for early disease detection, and monitor therapeutic efficacy. The IVIF supports all 7 programs at HCC, and has contributed to high impact publications in Immunity, Cancer Cell, Theranostics and Nature Communications, among other journals. IVIF had 76 users of which 66 were HCC investigators. Of the 66 HCC users, 42 had peer-reviewed funding. The Specific Aims of the IVIF: (1) Assess biomarker expression throughout cancer treatment using a single modality or a combination of modalities, both clinically and pre-clinically; (2) provide non-invasive imaging services for monitoring therapeutic efficacy in humans and animal models of cancer; (3) provide standard imaging assessment services to evaluate all types of treatment response using the FDA-approved and other standard imaging assessment criteria; (4) provide and incorporate novel imaging analytics such as radiomics and radiogenomics for clinical and preclinical tumor characterizations; and (5) develop novel imaging algorithms, advanced imaging analytics, radiotracers, and contrast agents for clinical and pre-clinical oncological imaging to monitor and evaluate treatment response and agents for targeted radionuclide therapy. Key Services Include: (1) PET radiotracer development and production for human PET-CT and PET-MRI; (2) pre-clinical PET-CT and clinical or preclinical assessment of biomarker expression during cancer treatment; and (3) developing methods for monitoring drug treatments and other types of therapy with PET-CT, CT, and/or MRI through the use of molecular imaging, standard imaging assessments, tumor volumetrics, radiomics and radiogenomics.

摘要：体内成像设备（IVIF） 癌症管理的进步需要开发新的治疗方法和最先进的成像技术 需要技术来评估对这些疗法的反应。希尔曼癌症中心（HCC）体内 IVIF成像设备提供了新的定量成像技术， 与有效癌症治疗相关的事件和免疫治疗反应。高级成像验证 需要特异于相关细胞过程的技术来检测和测量 新型抗癌疗法并测量早期杀肿瘤反应。作为该设施的一部分，PET示踪剂 靶向肿瘤微环境中的各种肿瘤标志物和免疫细胞，以及互补的 光学和磁共振方法，正在开发的敏感性和特异性定量药物癌细胞 交互. IVIF为在体内啮齿动物模型中测试PET示踪剂提供了关键的共享资源， 癌症并通过定量成像试验验证人类有前途的药物。的总体目标 IVIF将为HCC研究者提供临床前和临床成像服务，以协助可视化 生物标志物的作用机制，提供早期疾病检测的方法，并监测治疗 功效IVIF支持HCC的所有7个项目，并在2015年为高影响力的出版物做出了贡献。 Immunity，Cancer Cell，Theranostics和Nature Communications等期刊。IVIF有76个用户， 其中66人是HCC研究者。在总部合同委员会的66个用户中，有42个用户的供资经过同行审查。 IVIF的具体目的：（1）使用单一的生物标志物评估整个癌症治疗过程中的生物标志物表达。 临床和临床前的模态或模态组合;（2）提供无创成像 监测人类和动物癌症模型的治疗效果的服务;（3）提供标准 影像学评估服务，使用FDA批准的和其他 标准成像评估标准;（4）提供并结合新的成像分析，例如放射组学 和放射基因组学用于临床和临床前肿瘤表征;和（5）开发新的成像 用于临床和临床前的算法、高级成像分析、放射性示踪剂和造影剂 肿瘤学成像以监测和评估治疗反应和用于靶向放射性核素治疗的药剂。 主要服务包括：（1）人体PET-CT和PET-MRI的PET放射性示踪剂开发和生产;（2） 临床前PET-CT和癌症治疗期间生物标志物表达的临床或临床前评估; 以及（3）开发用于监测药物治疗和其它类型的治疗的方法，所述方法具有PET-CT，CT， 和/或MRI，通过使用分子成像、标准成像评估、肿瘤体积测定， 放射组学和放射基因组学。